Ingalls & Snyder LLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ingalls & Snyder LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,388 shares of the medical research company’s stock after buying an additional 41 shares during the period. Ingalls & Snyder LLC’s holdings in Thermo Fisher Scientific were worth $722,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Castle Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 3.4% in the fourth quarter. Castle Wealth Management LLC now owns 2,861 shares of the medical research company’s stock valued at $1,490,000 after purchasing an additional 94 shares in the last quarter. McClarren Financial Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $157,000. Fiera Capital Corp grew its position in shares of Thermo Fisher Scientific by 11.2% in the fourth quarter. Fiera Capital Corp now owns 155,552 shares of the medical research company’s stock valued at $80,923,000 after purchasing an additional 15,629 shares in the last quarter. Three Bridge Wealth Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $273,000. Finally, Naples Global Advisors LLC grew its position in shares of Thermo Fisher Scientific by 5.7% in the fourth quarter. Naples Global Advisors LLC now owns 756 shares of the medical research company’s stock valued at $394,000 after purchasing an additional 41 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Bank of America decreased their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Bernstein Bank upped their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Scotiabank upped their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock valued at $11,231,699 over the last quarter. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of NYSE TMO opened at $532.63 on Friday. The stock has a market cap of $203.73 billion, a P/E ratio of 32.22, a PEG ratio of 3.18 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The business’s fifty day simple moving average is $548.21 and its 200-day simple moving average is $571.28.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.